First Patient Enrolls in Phase 2 Trial of ABX464, Potential Ulcerative Colitis Treatment

First Patient Enrolls in Phase 2 Trial of ABX464, Potential Ulcerative Colitis Treatment
A first patient has been enrolled in a proof-of-concept clinical trial of ABX464 as a possible treatment for people with moderate-to-severe active ulcerative colitis, its developer, Abivax, announced in a press release. The patient was enrolled at the University Hospitals Leuven, Belgium. The trial involves 17 other centers in seven European countries besides Belgium: France, Germany, Poland, Hungary, Czech Republic, Spain and Austria. ABX464 was first developed to be an oral, first-in-class, small molecule that might lessen or eliminate the HIV viral reservoirs, with the pote
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *